SCHEMBL234819

SCHEMBL234819

O=c1oc2cc(O)ccc2c2oc3ccccc3c12

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.85
MAPT P10636 5/20 0.85
MEN1 O00255 4/20 0.85
RECQL P46063 4/20 0.85
KMT2A Q03164 4/20 0.85
ESR2 Q92731 4/20 0.85
HPGD P15428 3/20 0.85
BLM P54132 3/20 0.85
MAOA P21397 3/20 0.85
ALDH1A1 P00352 3/20 0.85
GAA P10253 2/20 0.85
ESR1 P03372 2/20 0.85
MGAM O43451 1/20 0.85
NR1I2 O75469 1/20 0.85
LMNA P02545 1/20 0.85
GLA P06280 1/20 0.85
POLB P06746 1/20 0.85
THRB P10828 1/20 0.85
CSNK2A2 P19784 1/20 0.85
CSNK2B P67870 1/20 0.85

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30006760 1.00 KDM4E (0.85) KDM4EMAPTMEN1RECQLKMT2A
SCHEMBL30004934 1.00 KDM4E (0.85) KDM4EMAPTMEN1RECQLKMT2A
SCHEMBL15870371 1.00 KDM4E (0.85) KDM4EMAPTMEN1RECQLKMT2A
Coumestrol SCHEMBL22012 0.92 ESR2 (1.00) KDM4EMAPTMEN1RECQLKMT2A
Coumestrol SCHEMBL29453366 0.92 ESR2 (1.00) KDM4EMAPTMEN1RECQLKMT2A
SCHEMBL15870374 0.88 ESR2 (0.84) KDM4EMAPTMEN1RECQLKMT2A
SCHEMBL15864245 0.85 KDM4E (0.70) KDM4EMAPTMEN1RECQLKMT2A
SCHEMBL30602583 0.85 KDM4E (0.70) KDM4EMAPTMEN1RECQLKMT2A
SCHEMBL30482848 0.85 KDM4E (0.70) KDM4EMAPTMEN1RECQLKMT2A
SCHEMBL14177143 0.84 ESR1 (0.82) KDM4EMAPTMEN1RECQLKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120003273-A1 SUBSTITUTED BENZFUROCHROMENES AND RELATED COMPOUNDS FOR THE PREVENTION AND TREATMENT OF BONE RELATED DISORDERS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGISTRATION OF SOCIETIES ACT (ACT XXI OF 1860)) (IN) 2012-01-05 US claimed
EP-2346844-A1 SUBSTITUTED BENZFUROCHROMENES AND RELATED COMPOUNDS FOR THE PREVENTION AND TREATMENT OF BONE RELATED DISORDERS Council Of Scientific & Industrial Research (IN) 2011-07-27 EP claimed
WO-2010052734-A1 SUBSTITUTED BENZFUROCHROMENES AND RELATED COMPOUNDS FOR THE PREVENTION AND TREATMENT OF BONE RELATED DISORDERS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2010-05-14 WO claimed
EP-2346844-B1 SUBSTITUTED BENZFUROCHROMENES FOR THE PREVENTION AND TREATMENT OF BONE RELATED DISORDERS COUNCIL SCIENT IND RES (IN) 2017-09-20 EP disclosed
US-20150336977-A1 Coumestan, Coumestrol, Coumestan Derivatives and Processes of Making the Same and Uses of Same BG NEGEV TECHNOLOGIES & APPLIC LTD (IL) 2015-11-26 US disclosed
US-20150336977-A1 Coumestan, Coumestrol, Coumestan Derivatives and Processes of Making the Same and Uses of Same BG NEGEV TECHNOLOGIES & APPLIC LTD (IL) 2015-11-26 US disclosed
WO-2014106848-A1 COUMESTAN, COUMESTROL, COUMESTAN DERIVATIVES AND PROCESSES OF MAKING THE SAME AND USES OF SAME B.G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD. (IL) 2014-07-10 WO disclosed
US-20120003273-A1 SUBSTITUTED BENZFUROCHROMENES AND RELATED COMPOUNDS FOR THE PREVENTION AND TREATMENT OF BONE RELATED DISORDERS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGISTRATION OF SOCIETIES ACT (ACT XXI OF 1860)) (IN) 2012-01-05 US disclosed
US-20120003273-A1 SUBSTITUTED BENZFUROCHROMENES AND RELATED COMPOUNDS FOR THE PREVENTION AND TREATMENT OF BONE RELATED DISORDERS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGISTRATION OF SOCIETIES ACT (ACT XXI OF 1860)) (IN) 2012-01-05 US disclosed
US-20120003273-A1 SUBSTITUTED BENZFUROCHROMENES AND RELATED COMPOUNDS FOR THE PREVENTION AND TREATMENT OF BONE RELATED DISORDERS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGISTRATION OF SOCIETIES ACT (ACT XXI OF 1860)) (IN) 2012-01-05 US disclosed
EP-2346844-A1 SUBSTITUTED BENZFUROCHROMENES AND RELATED COMPOUNDS FOR THE PREVENTION AND TREATMENT OF BONE RELATED DISORDERS Council Of Scientific & Industrial Research (IN) 2011-07-27 EP disclosed
WO-2010052734-A1 SUBSTITUTED BENZFUROCHROMENES AND RELATED COMPOUNDS FOR THE PREVENTION AND TREATMENT OF BONE RELATED DISORDERS COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150336977-A1 Coumestan, Coumestrol, Coumestan Derivatives and Processes of Making the Same and Uses of Same CYP19A1, ESR1, GPER1 KDM4E 880/4885MAPT 1557/4885MEN1 954/4885
US-20120003273-A1 SUBSTITUTED BENZFUROCHROMENES AND RELATED COMPOUNDS FOR THE PREVENTION AND TREATMENT OF BONE RELATED DISORDERS AKR1C3, AKR1C4, SLC10A1 KDM4E 2194/4885MAPT 4821/4885MEN1 302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.